SANTERO was founded by Abel Garcia-Pino, Cédric Govaerts in 2021.

Who are SANTERO's investors?

SANTERO's investors include Newton Biocapital, Sambrinvest.

Where is SANTERO headquartered?

SANTERO is headquartered in Brussels, BE.

SANTERO

Brussels, BE · Founded 2021 · 24 employees on LinkedIn · 4 known investors

Find your way into SANTERO

1,765 people in our graph share verified history with the SANTERO team — schools, employers, funds. One of them is your warm intro.

Laura Buhlerunlockedknows Mark Beards · together at McKinsey & Company (overlapped)

×9knows the team · via Goldman Sachs

knows the team · via McKinsey & Company

knows the team · via Henley Business School

Santero is a Belgium-based biotech company developing antibacterial drugs, including an RSH inhibitor programme targeting Pseudomonas aeruginosa and multidrug-resistant pathogens. It runs drug discovery and preclinical development spanning computational chemistry, medicinal chemistry, and screening toward clinical development.

AI & Machine Learning Biotech Deep Tech Healthtech

Founders & leadership

SANTERO was founded in 2021 by Abel Garcia-Pino and Cédric Govaerts.

Abel Garcia-PinoinCo-founder & Scientific Advisor

Cédric Govaerts inCo-founder & Scientific AdvisorBoard Member at Fund+

Mark Beards inChief Executive OfficerMark Beards is CEO of Santero, a Belgium-based biotech company developing antibacterial drugs targeting multidrug-resistant pathogens. He has held leadership roles in medtech and biotech start-ups, large pharma, and investment banking, with experience in capital raising, product launches, and M&A.

Emilie RacineinCOO & Head of Chemistry

Cuong Vuong inChief Scientific OfficerHe brings over 16 years of pharmaceutical and biotech industry experience and more than 20 years in life sciences and infectious diseases research, with expertise spanning drug discovery, preclinical development, and project validation across small molecules, natural products, peptides, phages, and engineered lysins.

Valérie GallieninChief of Staff

Investors · 4

Newton BiocapitalBrussels

SambrinvestreportedCharleroi

Also in the syndicate · 2

SFPIMWE Life Sciences

Funding

SEC filings, press & company announcements

Undisclosed amountSeries AJun 2023
Newton Biocapital (lead), Sambrinvest, SFPIM, WE Life Sciences
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

SANTERO announces a €8 million Series A funding round led by Newton Biocapital to develop novel antibiotics in the fight against antimicrobial resistance. - BioSpacebiospace.com · Jun 2023

Frequently asked questions

What does SANTERO do?: Santero is a Belgium-based biotech company developing antibacterial drugs, including an RSH inhibitor programme targeting Pseudomonas aeruginosa and multidrug-resistant pathogens. It runs drug discovery and preclinical development spanning computational chemistry, medicinal chemistry, and screening toward clinical development.
Who founded SANTERO?: SANTERO was founded by Abel Garcia-Pino, Cédric Govaerts in 2021.
Who are SANTERO's investors?: SANTERO's investors include Newton Biocapital, Sambrinvest.
Where is SANTERO headquartered?: SANTERO is headquartered in Brussels, BE.